X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ABM-1310 is a selective, highly water-soluble, orally active, and brain-penetrant small molecule BRAF inhibitor, which is investigated for the treatment of relapsed and drug resistant primary malignant brain tumors.
Lead Product(s): ABM-1310
Therapeutic Area: Oncology Product Name: ABM-1310
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
ABM-1310 is a selective, highly water-soluble, orally active, and brain-penetrant small molecule BRAF inhibitor, which is investigated for the treatment of relapsed and drug resistant primary malignant brain tumors.
Lead Product(s): ABM-1310
Therapeutic Area: Oncology Product Name: ABM-1310
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2023
Details:
ABM-168 is a novel small molecule MEK inhibitor with high water solubility, cell and brain permeability. It has demonstrated anti-cancer efficacy in vitro in multiple cancer cell lines and in vivo in multiple xenograft animal models.
Lead Product(s): ABM-168
Therapeutic Area: Oncology Product Name: ABM-168
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2023
Details:
ABM-168 is a novel small molecule MEK inhibitor with high water solubility, cell and brain permeability. It has demonstrated anti-cancer efficacy in vitro in multiple cancer cell lines and in vivo in multiple xenograft animal models.
Lead Product(s): ABM-168
Therapeutic Area: Oncology Product Name: ABM-168
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2023
Details:
IND application for ABM-1310, a new-generation BRAF inhibitor has been approved by the NMPA to conduct Phase 1 clinical trials in patients of advanced solid tumors with BRAF mutation in China, primary goal of the study is to determine the optimal dose.
Lead Product(s): ABM-1310
Therapeutic Area: Oncology Product Name: ABM-1310
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
Details:
The first cancer patient has been successfully enrolled and dosed with ABM-1310 in the Phase 1. It demonstrated superior properties in pre-clinical animal models, is a highly selective, highly water-soluble, orally active, and brain-penetrant small molecule BRAF inhibitor.
Lead Product(s): ABM-1310
Therapeutic Area: Oncology Product Name: ABM-1310
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
